Minor adverse events not leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · adults with basal cell carcinoma of the skin
Radiotherapy may leads to higher recurrence at 3 years compared with surgical excision (with or without frozen section margin control) (low certainty).
2 findings from 1 review
Cosmetic outcome (good/excellent) · adults with basal cell carcinoma of the skin
Radiotherapy probably leads to lower cosmetic outcome (good/excellent) compared with surgical excision (with or without frozen section margin control) (moderate certainty).
1 finding from 1 review
Pain · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early treatment failure · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of herpes labialis during use of the preventative intervention (change in frequency of recurrence) · participants with recurrent herpes labialis
1 finding from 1 review
Severity of attack of recurrent herpes labialis during use of the preventative intervention (change in intensity) · participants with recurrent herpes labialis
1 finding from 1 review
Change in severity (pain) of herpes labialis · participants with recurrent herpes labialis
1 finding from 1 review
Change in severity (impairment of appearance) of herpes labialis · participants with recurrent herpes labialis
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.6 [0.45, 0.81]
324 participants
Moderate
Progression‐free survival · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.69 [0.52, 0.92]
324 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.71 [0.96, 3.03]
324 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 0.68 [0.09, 5.32]
324 participants
Low
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis
It is very uncertain whether etretinate with PUVA therapy as co‐intervention changes proportion of participants cleared or almost cleared in the short… compared with placebo with PUVA therapy (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found